Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee.
Cheitlin
M D
MD
Hutter
A M
AM
Brindis
R G
RG
Ganz
P
P
Kaul
S
S
Russell
R O
RO
Zusman
R M
RM
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D002318:Cardiovascular Diseases / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D003075:Coitus / Q000502:physiology; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D010879:Piperazines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones
D004791:Enzyme Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate; D015106:3',5'-Cyclic-GMP Phosphodiesterases